Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Axsome Therapeutics, Inc. (AXSM : NSDQ)

• Company Description    Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available. Number of Employees: 683

• Price / Volume Information    Yesterday's Closing Price: $122.96 Daily Weekly Monthly 20 Day Moving Average: 563,318 shares Shares Outstanding: 49.90 (millions) Market Capitalization: $6,135.89 (millions) Beta: 0.54 52 Week High: $139.13 52 Week Low: $75.56 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.07% 11.02% 12 Week 19.51% 8.50% Year To Date 45.33% 29.75%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL One World Trade Center 22nd Floor - NEW YORK,NY 10007 USA ph: 212-332-3241 fax: 212-320-0245 None http://www.axsome.com

• General Corporate Information    Officers Herriot Tabuteau - Chief Executive Officer and Chairman of the Board Nick Pizzie - Chief Financial Officer Roger Jeffs - Director Mark Coleman - Director Mark Saad - Director Peer Information Axsome Therapeutics, Inc. (CORR.) Axsome Therapeutics, Inc. (RSPI) Axsome Therapeutics, Inc. (CGXP) Axsome Therapeutics, Inc. (BGEN) Axsome Therapeutics, Inc. (GTBP) Axsome Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 05464T104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 49.90 Most Recent Split Date: (:1) Beta: 0.54 Market Capitalization: $6,135.89 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.76 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.26 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 44.28% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 83.97 Price/Cash Flow: - Price / Sales: 12.39 EPS Growth vs. Year Ago Period: 25.81% vs. Previous Quarter: -15.00% Sales Growth vs. Year Ago Period: 72.13% vs. Previous Quarter: 23.53% ROE 06/30/25 - -283.22 03/31/25 - -272.80 12/31/24 - -223.51 ROA 06/30/25 - -33.06 03/31/25 - -36.69 12/31/24 - -39.88 Current Ratio 06/30/25 - 1.57 03/31/25 - 2.03 12/31/24 - 2.11 Quick Ratio 06/30/25 - 1.51 03/31/25 - 1.96 12/31/24 - 2.04 Operating Margin 06/30/25 - -39.50 03/31/25 - -48.29 12/31/24 - -57.49 Net Margin 06/30/25 - -49.88 03/31/25 - -64.39 12/31/24 - -74.47 Pre-Tax Margin 06/30/25 - -50.05 03/31/25 - -64.37 12/31/24 - -74.44 Book Value 06/30/25 - 1.46 03/31/25 - 1.08 12/31/24 - 1.18 Inventory Turnover 06/30/25 - 2.61 03/31/25 - 2.39 12/31/24 - 2.19 Debt-to-Equity 06/30/25 - 1.66 03/31/25 - 3.48 12/31/24 - 3.22 Debt-to-Capital 06/30/25 - 62.41 03/31/25 - 77.67 12/31/24 - 76.31

Powered by Zacks Investment Research ©